Sermorelin (10mg Vial) Dosage Protocol

Overview

Sermorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates endogenous pituitary GH secretion. Originally approved for pediatric growth hormone deficiency, it is studied for adult off-label use to support physiologic GH output and IGF-1 levels.

Quick Start

Reconstitution: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration
Typical daily range: 200–500 µg once daily at bedtime
Measurement: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U-100 insulin syringe
Storage: Refrigerate lyophilized form at 2–8°C (36–46°F); use reconstituted vial within 10–14 days

Dosing Schedule (8-Week Gradual Protocol)

Week Daily Dose (µg) Units per Injection Volume (mL)
1–2 200 µg 6 units 0.06 mL
3–4 300 µg 9 units 0.09 mL
5–6 400 µg 12 units 0.12 mL
7–8 500 µg 15 units 0.15 mL

Frequency: Once daily subcutaneously at bedtime

Reconstitution Instructions

1. Draw 3.0 mL bacteriostatic water with sterile syringe
2. Inject slowly down vial wall; gently swirl to dissolve (do not shake vigorously)
3. Label with reconstitution date and refrigerate at 2–8°C, protected from light
4. Wipe vial stopper with alcohol before each use; use new sterile needle and syringe for each injection

Supplies Needed (8-Week Protocol)

Sermorelin vials: 2 vials (20 mg total; ~19.6 mg consumed)
Insulin syringes (U-100): 56 syringes (1 per day); recommend 100-count box
Bacteriostatic water: 1 × 10 mL bottle (uses ~6 mL)
Alcohol swabs: 112 swabs (2 per day); recommend 2 × 100-count boxes
Sharps container: One puncture-proof disposal container

Consider 30- or 50-unit syringes for weeks 1–4 to improve precision with low-dose measurements.

Storage Instructions

Lyophilized: Store at 2–8°C (36–46°F) in dry, dark conditions; do not freeze dry powder

Reconstituted: Refrigerate at 2–8°C (36–46°F); do not freeze mixed solution; use within 10–14 days when using bacteriostatic water

Allow vials to reach room temperature before reconstituting to aid dissolution. Inspect solution before each use (should be clear and colorless).

Protocol Overview

Goal: Stimulate endogenous pituitary GH release to support physiologic IGF-1 levels and anabolic processes
Schedule: Daily subcutaneous injections at bedtime for 3–6 months
Dose range: 200–500 µg daily (adult research range)
Timing: Bedtime administration leverages natural nocturnal GH pulse

How It Works

Sermorelin binds to GHRH receptors on pituitary somatotropes, stimulating endogenous pulsatile GH secretion. Unlike exogenous GH administration, it preserves physiologic feedback loops—GH release remains subject to normal negative feedback via somatostatin and IGF-1, reducing overdose risk. This pulsatile GH output promotes hepatic and peripheral IGF-1 production, supporting protein synthesis, lipolysis, and tissue repair.

Pediatric studies in idiopathic GH deficiency demonstrated significant improvements in height velocity over 6–12 months at 30 µg/kg nightly. Adult off-label use aims to restore age-related GH decline, though robust adult trial data remain limited.

Lifestyle Optimization

Sleep: Prioritize 7–9 hours nightly to maximize natural GH pulse
Nutrition: Consume 1.6–2.2 g protein/kg/day; avoid high-carb meals before bed
Exercise: Combine resistance training (3–5×/week) with moderate aerobic activity
Stress: Practice stress-reduction techniques; chronic stress elevates cortisol and suppresses GH
Avoid: Alcohol and smoking impair GH release

Potential Benefits

– Stimulates endogenous pulsatile GH release, supporting physiologic IGF-1 elevation
– In pediatric GH deficiency: significant improvements in height velocity over 6–12 months
– In adults (off-label): may support favorable body composition changes, energy, recovery, and metabolic markers (effects more modest than direct GH therapy)
– Preserves physiologic feedback, reducing supraphysiologic GH or IGF-1 risk versus exogenous GH

Common Side Effects

Injection-site reactions (most common): Transient redness, pain, or swelling (~17% incidence)
Rare systemic effects (<1%): Headache, flushing, dizziness, hyperactivity, drowsiness, hives
Thyroid considerations: ~6.5% developed subclinical hypothyroidism; untreated hypothyroidism can blunt GH response
– No serious acromegaly, hypoglycemia, or excessive IGF-1 elevations reported at recommended dosages

Injection Technique (Subcutaneous)

1. Gather materials: reconstituted vial, new insulin syringe, alcohol swab, cotton ball
2. Choose injection site: abdomen (2+ inches from navel), outer thigh, upper arm, or buttocks
3. Rotate sites systematically to prevent irritation (keep 1–2 inches apart)
4. Clean vial stopper and skin with alcohol swab; allow to dry
5. Draw dose equal to prescribed volume; expel air bubbles
6. Pinch skin fold; insert needle at 45–90° angle into subcutaneous tissue
7. Slowly depress plunger over 2 seconds; wait 1–2 seconds before withdrawing
8. Apply gentle pressure; do not rub site
9. Immediately dispose in sharps container; never recap needle

Important Considerations

Bedtime dosing is critical: Aligns with natural nocturnal GH pulse for optimal efficacy
Low-dose precision: Use 30- or 50-unit syringes for weeks 1–4 (≤10 units)
– Monitor IGF-1 levels at baseline and periodically (every 1–2 months)
– Check thyroid function if using long-term
– Document daily dose, time, and injection site for adherence tracking
– Rotate sites systematically to prevent lipohypertrophy

Troubleshooting

Pain or lumps: Ensure injecting into fatty tissue; avoid too shallow (skin) or too deep (muscle)
Injection-site reactions: Mild redness/swelling is common; allow longer breaks before reusing site
Cold solution discomfort: Warm refrigerated vial to room temperature (~30 minutes) before injection

Disclaimer

This content is for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Sermorelin is for research use only. Always consult qualified healthcare professionals before starting any peptide protocol. Individual responses vary; dosing should be tailored to specific health status, goals, and monitoring outcomes.